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Abstract
A hallmark of systemic sclerosis (SSc) is the development of
tissue fibrosis. Excessive production of several connective tis-
sue components normally present in the dermis, including type
I, III, V, and VI collagens as well as fibronectin and proteogly-
cans, is a consistent finding in the skin of SSc patients. Type
VII collagen is a major constituent of anchoring fibrils, present
in the skin at the dermal-epidermal basement membrane zone.
TGF-ft has been shown to upregulate the expression of the type
VII collagen gene. In this study, we assessed the expression of
type VII collagen and TGF-,6 in the skin of patients with SSc.
Indirect immunofluorescence showed an abundance of type VII
collagen in the patients' skin, including the dermis. Ultrastruc-
tural analysis of SSc skin revealed an abundance of fibrillar
material, possibly representing type VII collagen. The in-
creased expression of type VII collagen epitopes was accompa-
nied by the elevated expression of immunodetectable TGF-ftl
and TGF-,82. Dermal fibroblasts cultured from the affected indi-
viduals showed a statistically significant (P < 0.02) increase in
the expression of type VII collagen at the mRNA level, as de-
tected by reverse transcription-PCR with a mutated cDNA as
an internal standard, and increased deposition of the protein as
assessed by indirect immunofluorescence. Thus, type VII colla-
gen is abundantly present in SSc patients' dermis, a location not
characteristic of its normal distribution, and its aberrant ex-
pression may relate to the presence ofTGF-,8 in the same topo-
graphic distribution. The presence of type VII collagen in the
dermis may contribute to the tightly bound and indurated ap-
pearance of the affected skin in SSc patients. (J. Clin. Invest.
1994. 93:1709-1715.) Key words: systemic sclerosis * anchor-
ing fibrils * type VII collagen * tissue fibrosis * transforming
growth factor-,
Introduction
Systemic sclerosis (SSc)' is a connective tissue disease charac-
terized by fibrosis of the skin, subcutaneous tissue, and various
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1. Abbreviations used in this paper: 11F, indirect immunofluorescence;
NC, noncollagenous; RT-PCR, reverse transcription-PCR; SSc, sys-
temic sclerosis.
internal organs (1). The most prominent pathologic manifesta-
tion ofthe disease is an abnormal accumulation ofextracellular
matrix components, predominantly collagen types I and III
(2-4). More recent data have also shown an increased expres-
sion of type VI collagen, mainly in a perivascular location (5).
In vitro, fibroblast cultures established from SSc patients' in-
volved skin express increased amounts of collagens type I, III,
and V, fibronectin, and proteoglycans (6-1 1), and contain ele-
vated levels of a 1(I), a2(I), and a 1(111) collagen mRNAs (12-
14). Transient transfection assays have also shown increased
activity ofthe a2(I) collagen promoter-reporter gene construct
in SSc fibroblasts (15), suggesting enhancement oftype I colla-
gen gene expression at the transcriptional level.
TGF-3 consists ofa family ofclosely related cytokines. Two
members ofthe family, TGF-f31 and TGF-f32, have been impli-
cated in the pathogenesis of a variety of fibrotic diseases ( 16,
17), and several lines of evidence suggest that TGF-f3 plays a
critical role in the development of tissue fibrosis in SSc. For
example, TGF-f 1 has been shown to stimulate the synthesis of
various connective tissue components by normal fibroblasts in
vitro ( 1 8, 19), and when injected intradermally TGF-f. causes
tissue fibrosis (20). Furthermore, an abundance of TGF-f in
the skin of SSc patients (21, 22) and the responsiveness of SSc
fibroblasts to stimulation by TGF-3 (23, 24) make this growth
factor a potential candidate molecule in the pathogenesis of SSc.
Type VII collagen consists of three identical a I(VII)
chains, each composed of a long collagenous triple-helix
flanked by globular amino- and carboxy-terminal noncolla-
genous domains (25-27). Type VII collagen is present in hu-
man tissues in a restricted distribution, almost exclusively in
the basement membrane zone below stratifying squamous epi-
thelia of the skin, mucous membranes, and the cornea of the
eye. Type VII collagen is the predominant, if not the exclusive,
component of anchoring fibrils, attachment structures which
ensure the integrity of the cutaneous basement membrane
zone (for reviews see references 27, 28). Under in vitro condi-
tions, type VII collagen is synthesized primarily by epidermal
keratinocytes, but dermal fibroblasts have also been shown to
express the type VII collagen gene at a very low level (29, 30).
The synthesis oftype VII collagen can be upregulated by TGF-
,B1 and TGF-f2 both in keratinocyte and fibroblast cultures
(30, 31).
The aim of the present study was to assess the expression
and distribution of type VII collagen and TGF-f in the skin of
SSc patients and to examine the expression of the type VII
collagen gene in SSc fibroblast cultures.
Methods
Patients. This study was performed on skin specimens from seven pa-
tients, six of them having a definitive diagnosis of diffuse SSc and one
being suggestive of SSc (Raynaud's phenomenon and positive test for
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antinuclear antibody). Also, dermal fibroblast cultures were estab-
lished from eight patients with diffuse SSc of recent onset. In one case,
the skin specimens and cultured fibroblasts were obtained from the
same patient. The diagnosis of SSc was made according to the criteria
of the American College of Rheumatology (formerly American Rheu-
matism Association) (32), and none ofthe patients had a limited form
of SSc. Clinical features and laboratory findings ofthe 15 patients (S1-
S 15) are summarized in Table I. Control fibroblast cultures were estab-
lished from eight age- and sex-matched healthy individuals, and nor-
mal skin specimens were obtained from three healthy individuals.
Full thickness excisional skin biopsies were obtained from the lead-
ing edge of the fibrotic process on the dorsal forearm of SSc patients
and from site-matched areas from healthy individuals. Each specimen
was cut into two pieces. One part was immediately frozen in liquid
nitrogen, and 5-Mim-thick frozen sections were used for indirect immu-
nofluorescence (IIF). The second piece was used to establish fibroblast
cultures. For IIF, cells were grown on chamber slides (Nunc, Inc., Na-
perville, IL) to subconfluency. All fibroblast cultures were maintained
in DME supplemented with 10% FCS. In experiments testing the ef-
fects of TGF-3, the cells were rinsed with PBS and replaced in DME
containing 1% FCS 3 h before addition of 10 ng/ml TGF-#31 orTGF-,32
(provided by Dr. David R. Olsen, Celtrix Laboratories, Santa Clara, CA).
Reverse transcription-PCR (RT-PCR) amplification of type VII
collagen mRNA transcripts. 1 Mug of total RNA isolated from fibroblast
cultures (passages 4-6), established from the skin of healthy normal
donors or from SSc patients, was used to synthesize the first strand
cDNA with avian myeloblastosis virus reverse transcriptase (Bethesda
Research Laboratories, Gaithersburg, MD) using oligo-dT2-18 primers
(33). The total amount ofcDNA synthesized served as a template for
the subsequent PCR amplification, and the reaction was catalyzed by
Taq polymerase (Boehringer Mannheim Corp., Indianapolis, IN) in
the presence of 15 MCi of [a32P]dCTP and 25 pmol of two primers
defining a 382-bp segment in the 3'-end of type VII collagen mRNA
(34). The primers used were: the upstream primer, 5'-AAT-
GATGGCTCTGCTGGTCC-3'; the downstream primer, 5'-CATG-
CAGAGGAGGAAGAGGCG-3' (Fig. 1). Amplification was per-
formed for 25 cycles (94°C for 45 s, 61 °C for 45 s, and 72°C for 45 s)
using a thermal cycler (Coy Laboratory Products Inc., Ann Arbor,
MI). Differences in the efficiency ofPCR amplification were corrected
for by using a cloned cDNA as internal standard which contained com-
plementary sequences for the same primers and yielded the same size
product but contained a single base substitution in the sequence
GAGAAG instead ofGAGATG found in the normal sequence (35).
The mutated PCR product could be cleaved by the endonuclease Earl
into 244- and 138-bp fragments (Fig. 1). This homozygous T-to-A
substitution has been detected in two siblings with recessive dystrophic
epidermolysis bullosa (35). The product of PCR amplification was
subcloned into the PCR 1000 vector (Invitrogen, San Diego, CA),
amplified, and the plasmid construct was linearized with restriction
enzyme digestion using EcoRI (Boehringer Mannheim Corp.). 100 pg
of the cDNA containing the mutated sequence (T-to-A substitution)
was used as an internal standard mixed with the cDNA template gener-
ated by RT-PCR from RNA isolated from fibroblast cultures estab-
lished from SSc patients or from matched control individuals. 200 pg of
cDNA containing the internal standard was used for experiments with
cDNA from TGF-#-stimulated fibroblasts.
Each PCR reaction product was extracted with phenol-chloroform,
digested to completion with the restriction enzyme Earl, and subse-
quently analyzed by electrophoresis on a 4% polyacrylamide gel (33).
The gel was exposed to x-ray film (X-Omat; Eastman Kodak, Roches-
ter, NY) at -70°C for varying time periods, and the autoradiographic
signals were quantitated by scanning densitometry in the linear range
of the autoradiograms. The intensity of the 382-bp band was normal-
ized by the signal from the 244-bp cleavage product derived from the
internal standard. Control experiments indicated that cleavage of the
PCR product containing the Earl site was complete (35).
IIF. The slides containing either skin sections or cultured cells were
rinsed with PBS and fixed with ice-cold 100% ethanol. For detection of
type VII collagen, after a 30-min incubation with 1% BSA in PBS, the
samples were exposed to an anti-type VII collagen mAb (36) (L3D;
provided by Dr. Robert Briggaman, University of North Carolina,
Chapel Hill, NC) for 45 min at room temperature. Similar procedures
were used for the detection ofTGF-, I or TGF-,#2 epitopes using mAbs
(provided by Dr. David R. Olsen, Celtrix Laboratories, Santa Clara,
CA). The slides were then rinsed with PBS and exposed to a rhoda-
mine-conjugated monoclonal anti-mouse IgG antibody (Cappel Labo-
Table 1. Clinical Characteristics ofPatients with Systemic Sclerosis
Patient Systemic involvement
Skin involvement Serum antibodies
Patient Raynaud's
number Age/sex Duration Degree* Pulmonary4 Renal Cardiact Gastrointestinal phenomenon ANAI Anti-TopoI/ACA"
yr %
S I 36/F < 1 25 - - + + + 2560 +/-
S2 58/M 4 14 + - + + + 5120 ND/ND
S3 57/F <2 54 - - + - + 500
S4 45/M < 1 45 - - - + + 640
S5 60/F < 1 >60 + - + + 640
S6 35/F < 1 26 - - + - + 500 ND/-
S7 56/F < 1 20 - - + + - 5120
S8 70/F < 1 45 - - + - + 2560
S9 54/F < 1 25 ND ND - ND + ND ND/ND
S10 31/F 2 22 - ND - ND + >2560
511 38/F 2 25 + - + - + 2560
S12 37/F <1 15 + + - + 1280
S13 26/F 3 25 - - - + + 5120
S14 34/M <1 1 + - + + 1280
S15 54/F <1 0 - - - - + 80
* Values indicate semiquantitative estimate of the percentage ofbody surface area that is affected clinically. The pulmonary and cardiac in-
volvement was determined as described previously (48). 1 ANA, antinuclear antibodies. 11 ACA, anticentromere antibodies. ' ND, no data available.
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Figure 1. Schematic representation of type VII collagen domain or-
ganization, as deduced from cloned cDNAs, and the genomic posi-
tions of primer sequences used for RT-PCR amplification of type VII
collagen mRNA transcripts. (A) Type VII collagen consists of a cen-
tral collagenous region depicting characteristic Gly-X-Y amino acid
sequence (filled boxes). This collagenous domain is flanked by a large
amino-terminal NC domain (NC- l) and a smaller carboxy-terminal
NC domain (NC-2) (hatched boxes). (B) The intron-exon organiza-
tion of the genomic segment corresponding to the collagenous/NC-2
junction in the mRNA (35), as delineated by a bar in A. The sizes
(basepair) of the introns (horizontal line) and exons either in the col-
lagenous (filled boxes) or NC domain (hatched boxes) are indicated.
(C) The positions and nucleotide sequences of the primers used for
PCR amplification ofa 382-bp segment from fibroblast mRNA. (D)
The nucleotide sequence of a 49-bp exon within the NC-2 domain.
The upper line depicts a conserved normal sequence (34) while the
lower line depicts a mutated sequence detected in two siblings with
recessive dystrophic epidermolysis bullosa (35). The mutated se-
quence was used as a template to develop a cloned cDNA which was
used as an internal standard for RT-PCR. As indicated in the text,
the T-to-A substitution creates a restriction enzyme site for the endo-
nuclease EarI, resulting in the cleavage ofthe 382-bp PCR amplimer
into 244- and 1 38-bp fragments.
ratories, Malvern, PA) for 45 min. Nonadherent secondary antibodies
were then rinsed off with PBS. Nonspecific staining was excluded by
performing staining reactions with the secondary antibody only.
Electron microscopy. For ultrastructural analysis, punch biopsies
from two affected patients were fixed in 2.5% glutaraldehyde, 0.1 M
sodium phosphate, pH 7.2, postfixed in OS04, dehydrated in ethanol,
and embedded in Spurr. 1-Mm-thick sections were stained in toluidine
blue, while thin sections were stained with uranyl acetate and lead
citrate, and the samples were examined in a transmission electron mi-
croscope (lOOCX; JEOL U.S.A. Inc., Peabody, MA) operated at 80 kV.
Results
RT-PCR demonstrates elevated expression oftype VII collagen
mRNA transcripts in cultured SScfibroblasts. To determine the
levels oftype VII collagen mRNAs in cultured SSc and control
fibroblasts, RT-PCR was performed with total RNA isolated
from cultures established from seven healthy donors and seven
SSc patients. An internal standard consisting of a cDNA tem-
plate with the identical sequence, with the exception ofa single
T-to-A nucleotide substitution which created a new restriction
site for Earl endonuclease (see Fig. 1), was included in each
reaction. Scanning densitometry of the RT-PCR products,
after correction by the value from the internal standard (see
Methods), demonstrated on the average an 3.4-fold higher
level of type VII collagen mRNA transcripts in fibroblast cul-
tures from SSc patients, as compared with those from healthy
donors (P < 0.02) (Fig. 2). Incubation with TGF-f 1 and TGF-
(32 increased the expression of type VII collagen in cultured
fibroblasts established from normal controls (5.3- and 6.7-fold,
respectively) and from SSc patients ( 1.5- and 1.3-fold, respec-
tively) (Fig. 3).
Demonstration ofelevated type VII collagen expression at
the protein level by IIF. To evaluate the expression oftype VII
collagen at the protein level, IIF with an mAb recognizing an
epitope in the amino-terminal noncollagenous (NC) domain
(NC- 1) (37) was performed on cultured SSc and control cells.
As reported previously (29), unstimulated dermal fibroblasts
from healthy controls display a faint, yet clearly detectable,
staining reaction (+) for type VII collagen epitopes (Fig. 4 A).
Fibroblasts from eight SSc patients were stained in parallel with
the same monoclonal anti-type VII collagen antibody (36). In
five cases, an intense (++) to very intense (+++) staining
reaction, as illustrated in Fig. 4 B, could be observed. In the
remaining three cases, no apparent difference between the con-
trol and SSc fibroblasts could be noted (not shown). Exposure
of control fibroblasts to either TGF-O1 or TGF-32 resulted in a
marked increase in the immunofluorescence, in accordance
with previous results (30, 31 ). The relative increase after stimu-
lation with TGF-f seemed somewhat less pronounced in SSc
fibroblasts, probably reflecting the higher baseline staining in
unstimulated control cultures. However, the intensity of the
immunofluorescence appeared to be equally strong in both
control and SSc fibroblasts after stimulation with TGF-#.
IIF of skin sections from healthy controls showed an in-
tense staining (+++ or ++++) for type VII collagen at the
dermal-epidermal junction, and similar staining was observed
at the basement membrane zone of the skin specimens from
SSc patients (Fig. 5). In addition, six out of eight SSc patients
382bp-A .,,
244bp
,
X # W aveii
iWO _ - 0
138bp_,
6
4
2
C ' 2 C3 C4 C5 C6 C7 S1 S2 S3 S4 S5 S6 S
Figure 2. RT-PCR of RNA isolated from fibroblasts of normal
healthy controls (Cl-C7) or from patients with SSc (Sl-S7). (A) Au-
toradiogram representing the 382-bp bands derived from amplifica-
tion of control or SSc fibroblast mRNA. The 244- and 138-bp bands
reflect the presence of fragments derived from the mutated internal
standard cDNA after digestion with EarI (see Fig. 1). (B) Ratios of
the 382- and 244-bp bands in each lane, as determined by densito-
metric scanning. The values represent the mean±SE from four sepa-
rate determinations of the intensity of the bands at different levels
of exposure to x-ray films. The mean value of SSc fibroblast type VII
collagen transcripts, in comparison with controls, is statistically higher
(P < 0.02) by Student's t test.
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TGFP1 - + - - + - - + - - - +
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Figure 3. Demonstration that TGF-# I and TGF-f32 increase type VII
collagen gene expression in cultured fibroblasts. Cells from two SSc
patients (SScI = S5 and SScII = S6 in Fig. 2) and matched control
cultures were incubated without (-) or with (+) 1O ng/ml ofTGF-,B
for 24 h. Type VII collagen mRNA levels were determined by RT-
PCR, as described in Methods and in Fig. 2, using an internal cDNA
standard. The 382-bp band represents endogenous mRNA, while the
244- and 1 38-bp bands result from digestion of the internal standard
by Earl. The digestion of the internal standard was complete, as
shown in the negative (NEG) control lane. The upper panel depicts
the autoradiogram of the gel containing 32P-labeled PCR products.
The lower panel indicates the relative ratios of 382- and 244-bp bands,
as determined by scanning densitometry (mean±SD of four separate
determinations on the linear range ofexposure ofthe autoradiograms).
showed an intense (++ or +++) staining reaction throughout
the dermis (Fig. 5, B and C, and Table II). In two cases (S4 and
S5), the staining reaction appeared to be more intense in the
reticular dermis, as compared with the papillary dermis (Fig. 5
B). In two patients (S2 and S3), the presence oftype VII colla-
gen was also noted within the epidermis (Fig. 5 C), and in one
patient (S3) distinct staining reaction for type VII collagen was
also detected in the subcutaneous tissue (Fig. 6 A). Parallel
staining ofcontrol skin specimens revealed essentially negative
staining reaction (- or ±) in the epidermis and dermis (Fig. 5
A) and the subcutaneous adipose tissue (Fig. 6 B).
Detection of TGF-,# epitopes in the affected skin ofSSc pa-
tients. Since TGF-,3 has previously been shown to upregulate
type VII collagen gene expression both at the protein and
mRNA levels (30, 3 1 ), the presence of TGF-#3l and TGF-f2
epitopes was also evaluated in the skin specimens of the eight
patients with SSc and compared with control skin samples
from three healthy individuals. In healthy individuals, the pres-
ence ofTGF-#3I and TGF-I2 epitopes could be observed in the
epidermis (±, +, or ++), while the staining reaction in the
dermis was essentially negative (Fig. 7, A and B). In SSc pa-
tients, TGF-#3l and TGF-f32 epitopes were clearly detectable in
the epidermis and dermis of all patients studied (Fig. 7, C and
D, and Table II). Staining for TGF-l3I and TGF-ff2 epitopes in
subcutaneous tissue was also performed in one healthy control
and three patients with SSc. In the healthy individual, staining
for both forms of TGF-f3 was entirely negative (Fig. 6 D and
Table II). In contrast, in two out of three patients with SSc,
both TGF-f3I and TGF-,32 epitopes were detected (Fig. 6 Cand
Table II). In general, a correlation could be observed between
the relative staining intensity of TGF-f and type VII collagen
epitopes in the dermis of SSc patients (Table II).
Electron microscopy. Ultrastructural analysis of the skin
from two affected patients revealed a normal appearing epider-
mis with a continuous basement membrane and anchoring fi-
brils, and the subepidermal region, as expected, contained an
increased amount of collagen arranged in thick interweaving
bundles (not shown). Of particular interest was the observa-
tion that the deeper dermis contained numerous aggregates of
filamentous structures which were interspersed between the
collagen bundles and the elastic fibers. These filaments were
15-20 nm in thickness and up to 200 nm in length. In some
instances, these filaments interacted end-to-end, formed elon-
gated structures, and occasionally showed a curvilinear confor-
mation similar to that observed in the anchoring fibrils asso-
ciated with the basement membrane at the dermal-epidermal
junction (28). These findings suggest that these filaments may
represent abnormal type VII collagen aggregates, but their ex-
act biochemical composition could not be determined.
Discussion
Type VII collagen is the major, if not the exclusive, constituent
of anchoring fibrils (38). These fibrils play an essential role in
Figure 4. IIF staining with anti-type VII collagen mAb L3D of fibro-
blast cultures established from a healthy control, C5 (A), and a sex-
and age-matched SSc patient, S5 (B).
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Figure 6. The presence of type VII collagen and TGF-# I epitopes in
the subcutaneous tissue of a patient, S3 (A and C, respectively), while
the immunostaining of the subcutaneous adipose tissue from a nor-
mal control skin with respective antibodies (B and D) is entirely neg-
ative.
table forms of dystrophic epidermolysis bullosa (27, 39, 40),
and an acquired autoimmune disease, epidermolysis bullosa
acquisita (41 ). To date, no example ofpathologic upregulation
of type VII collagen in an ectopic topographic location has
been described. However, a previous ultrastructural study has
indicated the presence of anchoring fibrils in the lung tissue of
patients with idiopathic pulmonary fibrosis; these fibrils were
not detected in normal lungs (42). Since the anchoring fibrils
observed in the lung tissue resemble those found in normal
skin, it is conceivable that type VII collagen levels may also be
increased in the fibrotic lung tissue in SSc.
Figure 5. IIF staining of type VII collagen epitopes within normal skin
(A) and in two patients with SSc, S4 and S2 (B and C, respectively).
Note the strong linear staining for type VII collagen epitopes in the
cutaneous basement membrane zone in all three specimens, as indi-
cated by an arrow in A. The presence of type VII collagen epitopes is
demonstrated in the reticular dermis in a patient with SSc (B, open
arrow) and also within the epidermis (C, asterisk).
stabilizing the association of the basement membrane to the
underlying dermis and, consequently, provide integrity to the
cutaneous basement membrane zone (28). In normal skin, the
distribution of type VII collagen is essentially restricted to the
dermal-epidermal basement membrane zone, the site of an-
choring fibrils. Decreased expression oftype VII collagen and/
or impaired assembly ofthis collagen into anchoring fibrils has
been associated with blistering skin diseases, including the heri-
Figure 7. Immunofluorescence staining of normal human skin (A and
B) or skin from a patient (S3) with SSc (C and D) with antibodies
recognizing the epitopes for TGF-fll (A and or TGF fl2 (B and D).
Note the presence of a relatively faint, yet clearly detectable staining
in the epidermis of normal skin (A and B), while the staining is
markedly enhanced in the SSc patient's skin (C and D).
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Table II. Presence of Type VII Collagen, TGF-#I, and TGF-132 Epitopes in the Skin and Subcutaneous Tissue of SSc Patients and
Healthy Controls*
Type VII collagen TGF-ftl TGF-B2
Patient Epidermis BMZt Dermis Subcutaneous Epidermis Dermis Subcutaneous Epidermis Dermis Subcutaneous
Controls
C - ++++ - NS ++ +/- NS + - NS
C2 - ++++ +/- NS ++ + NS + +/- NS
C3 - ++++ +/- - + +1- - +1- +1- -
SSc patients
S2 ++ ++++ +++ +1_ ++++ ++++ + +++ +++ +
S9 - ++++ +/- NS ++ + NS + + NS
S10 ++ ++++ +++ ++ ++++ +++ + ++ +
511 - ++++ +++ +/- ++ ++ NS ++ + NS
S12 +/- +++ ++ +1- ++ ++ +/- ++ + +
S13 +/- +++ ++ NS ++ ++ NS ++ + NS
S14 - +++ ++ NS ++ ++ NS ++ + NS
S15 - +++ +/- NS + + NS + +/- NS
* The intensity of the staining reaction was semiquantitatively expressed as follows: -, negative; +/-, very faint; +, faint; ++, intense; +++ or
++++, very intense; NS, not studied. * BMZ, basement membrane zone.
The results of our study demonstrate that in SSc skin type
VII collagen is present in high amounts, not only in its expected
location at the basement membrane zone but also in the der-
mis. Ultrastructural studies showed an abundance of fibrillar
structures, which may represent type VII collagen, in the der-
mis of SSc patients. The accumulation of type VII collagen in
SSc skin was accompanied by the presence of TGF-f 1 and
TGF-32 epitopes. Further studies performed in vitro on der-
mal fibroblasts showed increased expression of type VII colla-
gen in SSc cells at the mRNA and protein levels. Also, TGF-flI
and TGF-j32 further upregulated the expression of type VII
collagen both at themRNA and protein levels. Although upreg-
ulation was noted in both normal and SSc fibroblasts, the nor-
mal cells appeared to be more responsive to TGF-,B stimula-
tion, probably because oflower baseline level oftype VII colla-
gen expression in unstimulated control cultures. The higher
baseline level ofexpression oftype VII collagen in SSc cultures
may result from the exposure ofthe cells to TGF-,B in vivo, and
the attenuated response of SSc fibroblasts to TGF-, is consis-
tent with earlier data demonstrating unresponsiveness of SSc
cells to growth factors ( 15, 43). Also, there was a general corre-
lation between the relative intensity of staining reaction of
TGF-,B and type VII collagen epitopes within individual skin
specimens. Collectively, these results suggest that the abun-
dance of type VII collagen in SSc dermis may result from in-
creased local expression of TGF-f3.
Clinically, induration and thickening of the skin which is
tightly bound to the underlying tissue are the hallmark of SSc.
The presence oftype VII collagen and fibrillar structures in the
dermis may provide an explanation for this appearance of the
affected skin in SSc patients, and this effect could be expected
to be detectable only in the affected area ofthe skin. The accu-
mulation of type VII collagen in the skin could result from
upregulation of the corresponding gene by TGF-,B. In this con-
text, it is of interest to note that TGF-f31 has been shown to
increase its own expression in an autocrine manner, while
TGF-32 increases the expression ofTGF-#31 and TGF-f32 (44).
Consequently, an early increase in the local expression ofTGF-
fi 1 or TGF-,B2 could perpetuate their expression, thus resulting
in continued expression oftype VII collagen and other TGF-j3-
responsive genes in chronic fibrotic conditions. Thus, attempts
to counteract the effects of TGF-3 with other cytokines (45,
46) or to inhibit type VII collagen gene expression by novel
approaches, such as the use of antisense oligomers (47), might
be helpful in preventing the progression or even in reversing
some of the clinical manifestations of SSc.
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